Extended Data Fig. 10: Combinatorial treatment of mavrilimumab with immune-checkpoint blockade synergizes for anti-tumour immunity without off-target effects in EPZFTA-RELA mice.
From: Childhood brain tumors instruct cranial hematopoiesis and immunotolerance
a, Experimental design for the treatment of 3 week-old ZFTA-RELA EPZFTA-RELA-bearing mice with four weekly intravenous injections of Vehicle IgG isotype control (13 mg/kg, n = 5), anti-CTLA-4 (3 mg/kg, n = 4), mavrilimumab (10 mg/kg, n = 7) or combination of anti-CTLA-4 and mavrilimumab (n = 6). b, Quantification of the proportion of macrophages, monocytes, B cells, neutrophils, CD4 T cells and CD8 T cells, within the brain, dura, spleen, tibia and skull bone marrow of treated mice. A linear mixed-effects model was applied to test for interaction across strata, with skull bone marrow as the reference, Wald z-tests on contrasts relative to vehicle with Bonferroni correction for multiple comparisons (two-sided). Illustration in a created using BioRender.com.
